Abstract

Objective: The aim of the present study is to investigate the effects of Hordeum vulgare aqueous extract (HVE) in a sub-chronic depression rat model.


Methods: Thirty male rats were randomly divided into five groups: the first group served as a control group; the second group received i.p. injection of reserpine (Res) (0.5 mg/ kg) for 20 days, the third group received i.p. injection of reserpine plus fluoxetine (Res + Flux) (10 mg/kg p.o.) for 20 days, the fourth group received i.p. injection of Res plus HVE (1,000 mg/kg p.o.), and the fifth group received Res + Flus +HVE. Behavioral tests were measured on the 21st day of the experiment, then rats were decapitated to determine liver function [alanine transaminase, aspartate transaminase, TP, Alb, Glob, A/G), brain monoamines and their metabolites (NE, DA, 5-HT, HVA, DOPAC, 5HIAA), oxidative and nitrositive stress markers (MDA, glutathione, oxidized glutathione, NO, SOD, 8OHdG) and purinergic cell capacity (ATP, ADP, AMP).


Results: Obtained data showed neuro-degenerative effect of Res and deteriorative manifestation in liver function. Moreover, flux treatment showed an attenuated deterioration, manifested by Res for monoamines and its metabolites, and subsequently stabilized behaviors and decreased depression status with behavioral tests indicators. On the other hand, it showed initial indicators of liver alteration, presented by serum liver function and histological examination. In addition, treatment with HVE showed amelioration for behavioral, neurochemical functions, and decreased oxidative stress. The results were confirmed by the histological examination.


Conclusion: HVE ameliorate depression induced by Res, stimulates monoamines and antioxidant status, decrease oxidonitrositive markers and increases cell energy capacity without side effects on liver, contrasting to selective serotonin re-uptake inhibitors, which produces initial indicators of liver damages.


Introduction

Depression is one of the most prevalent diseases in the world. Depression is a state of complete physical malaise, which affects morbidity, general health, sleep quality and eating, and subsequently disrupts physiological and neurological homeostasis1. Causes of depression may have various sources. Depression accompanied by anxiety, which shows no clear differences between the symptoms of depression and anxiety. Bipolar depression, is accompanied by mania, a state of “high spirits”, which results in increased activity and decreasing need for sleep2. The causes of depression are not known exactly, however, as with many other psychiatric illnesses, it is believed that there are several biochemical, genetical, and environmental factors that may cause depression3. There is an evidence that people who suffer from depression have physical changes in the brain. In addition, hormonal imbalance can also cause this disorder4. Some studies have shown that depression is more common in people with family members with history of the disease, encouraging researchers to seek out the genes that cause the disease5,6,7. Environmental factors also play a critical role in depression. Depression may occur as a result of drug addiction, certain medications, or as a result of stressful life events8. On the other hand, diseases, such as cancer, thyroid disease, and chronic pain, are associated with an increased risk of depression. Both environmental and genetic factors are likely to interact to facilitate the development of the disease in a complete and rapid manner9. Fluoxetine, an antidepressant drug, acts as a selective serotonin reuptake inhibitor (SSRI), which has better overall safety and tolerability than older antidepressants10. However, SSRIs has shown with the frequency of side effects in clinical trial data11. The most troubling adverse events seen during long-term SSRI therapy may include weight gain, sexual dysfunction, as well as sleep disturbance. In depth, SSRI improves an opportunity for more available neurotransmitters to interact with any of these receptors or sub-type receptors12. In addition, SSRI-induced skin reactions and gastrointestinal disturbances are the most frequently reported side effects13,14. Barley (Hordeum vulgare) is considered as one of the natural substances that can improve public health. Barley is one of the famous plants that is used in the treatment of many diseases, as it contains many nutrients (such as proteins, amino acids, dietary fiber, antioxidants, vitamins, and carbohydrates)15. Strengthening the immunity may be due to a high level of vitamin C, which is higher in barley than orange. Barley is capable of preventing osteoporosis, since it is rich in minerals such as phosphorus, one of the most important elements for bones and teeth formation16. Chen found that barley contained vitamin E, a powerful antioxidant with the ability to cross the cerebral blood barrier17. Vitamin E is found in a high concentration in brain tissue and contributes to the synthesis of a number of neurotransmitters, such as dopamine. In addition, the presence of high amounts of vitamin (E) in blood stream stimulates mental functioning at all ages and protects the brain from degenerative diseases, including Alzheimer's disease and strokes. Vitamin E is especially important for the maintenance of older brains, which helps to reduce appearance of cerebrovascular diseases and strokes18.

The present study is aimed at examining possible protective effects of the H. vulgare extract against depression, induced by reserpine, and side effects of chemical drug (fluxitine) in a sub-chronic model of depression.

Methods

Chemicals

2,2-Diphenyl-1-picrylhydrazyl (DPPH) Merk EC Number 217-591-8. Methanol (HPLC grade) purchased from Loba Co, India. Perchloric acid purchased from Loba Co, India. Sulphosalsilic acid and P-aminobenzyl glutamate and pyrogallol purchased from TMMEDIA Co, India. The 1,1,3,3-tetraethoxypropane, glutathione (GSH) and oxidized glutathione (GSSG) from Sigma Aldrich (USA). Potassium dichromate, monobasic potassium phosphate, nitrites and nitrate were from Al Nasr chemicals, Abozabal (Qualybia, Egypt). All used chemicals were either HPLC or analytical grade. Neurotransmitters and cell energy purchased from Merck (NE CAS Number: 51-41-2; DA CAS Number: 62-31-7; 5HT CAS Number: 50-67-9; ATP CAS Number: 34369-07-8; ADP CAS Number: 20398-34-9; AMP CAS Number: 4578-31-8). 8-Hydroxy-2′-deoxyguanosine sigma CAS Number 88847-89-6. All spectrophotometer Kits were purchased from Biodiagnostic 29 El-Tahrer St.—Dokki—Giza—Egypt.

Animals

Adult male albino rats weighting about 150 ± 15 g were used in the present study. Animals were kept under normal laboratory conditions in the animal house of National Organization of Drug Control and Research for 1 week before the start of the experiment. Rats were to fed according to the uniformity diet.

Preparation of plant extract

The air-dried powdered of H. vulgare seeds (950 g) were extracted with 30% ethanol in soxhlet apparatus for 24 hours. The extract was evaporated to dryness under reduced pressure to give approximately 7.6% w/w solid yield residues. The yield was stored at 4ºC until used.

Assay of H. vulgare amino acids

Determination of H. vulgare amino acids seeds extract was measured and explained at Figure 1 via HPLC UV detector at 254 nm and ammonium acetate gradient buffer, combined with acetonitril (pH 5.7), according to the method of Saunders et al.19.

Figure 1 . Amino acids constituent of Hordeum vulgare seed extract. 1- ASP: 6.21; 2- GLU: 20.8; 3- SER: 4.22; 4- GLY: 4.35; 5- HIS: 2.38; 6- THR: 3.74; 7- ALA: 4.59; 8- ARG: 5.55; 9- PRO: 9.43; 10- TYR: 3.43; 11- VAL: 5.43; 12- METH: 1.75; 13- CYS: 2.69; 14- ILE: 3.94;15- LEU: 7.5; 16- PHYN: 5.46; 17- TRYP: 1.04; 18- LYS: 3.76.

Determination of free radical scavenging assay (DPPH)

The radical scavenging activity of HV aqueous extract was determined according to the method of previous study20, described by Siddhuraju 21, with different doses of extract (50, 100, and 200 μg/ml) at 517 nm. The interpretation of lower absorbance indicates high free-radical scavenging activity. The respected result showed antioxidant properties of each extract, compared to rutin of the same concentration as follows: 68%, 79%, 86% for rutin and 34%, 48%, 52% for H. vulgare aqueous extract (HVE), respectively.

Experimental design

After 1 week of acclimatization period, male rats were divided randomly into five equal groups, each of six rats. Group 1 kept as control, feeding on basal diet, group 2 received reserpine i.p (0.5 mg/ kg) for 20 days day other day22, group 3 received reserpine plus Fluxotine (10 mg/kg p.o)23 for 20 days, group 4 received reserpine plus H. vulgare seed 70% ethanolic extract (1,000 mg/kg p.o) for 20 days. Group 5 received reserpine plus Fluxotine and H. vulgare for 20 days24. Rats were grouped and housed in a conventional clean facility, according to the guidelines of the Institutional Animal Ethics Committee of NODCAR. All the experimental procedures were carried out in accordance with international guidelines for the care and use of laboratory animals.

Collection of blood samples

At the end of the experiment, blood samples were withdrawn from the retro-orbital vein of each rat, under light anesthesia by diethyl ether, according to the method described by Moore (2000)25. Blood was allowed to coagulate and then centrifuged at 3,000 rpm for 15 minutes. The obtained serum was used to estimate the activities of liver function enzymes, total protein, total lipids, and lipid peroxidation.

Preparation of brain samples

Immediately after blood sampling, animals were sacrificed by cervical dislocation and the brain tissues were rapidly removed, washed in ice-cooled saline, plotted dray, and weighed. A weighed part of each brain was homogenized, using a homogenizer (Medical instruments, MPW-120, Poland), with ice-cooled saline (0.9%NaCl) to prepare 20% w/v homogenate. The homogenate was then centrifuged at 4,000 rpm for 5 minutes. The aliquot was used for the assessment of monoamines, oxidative stress markers and purenergic cell energy.

Methods

Behavioral study

Open field

The open field apparatus was constructed of white plywood of 72 × 72 cm with 36-cm walls. Blue lines were drawn on the floor with a marker and were visible through the clear Plexiglas floor. The lines divided the floor into sixteen 18 × 18 cm squares. A central square (18 cm × 18 cm) was drawn in the middle of the open field26. 70% ethyl alcohol was used to clean the open field maze for each rat to avoid odor cues. The following conditions were measured. Grooming: the duration of time, which animal spent licking or scratching while stationary. Rearing: frequency of standing on their hind legs in the maze. Center Square Duration: the duration time of rats spent in the central square. Peripheral Square Duration: the duration time of rats spent in the peripheral square. Urination: number of puddles or streaks of urine. Defecation: number of fecal pellets produced.

Forced swim

The rats were examined in a cylindrical container (50 × 20 cm) filled with 30 cm of 22ºC water. Generally, in this test, the water level does not let the rat rest on its tail or run away from the cylinder by climbing out. Each rat was placed in the water for 6 minutes. The time spent floating (represented immobility) was scored during the last 4 minutes. The time spent immobile was considered as an index of depression-like behavior in rodents27.

Physiological study

Determination of transaminases (AST and ALT)

Aspartate transaminase (AST) and alanine transaminase (ALT) were determined, following a colorimetric method according to Reitman and Frankel28, using reagent kit by QCA-Spain. The Principle: Aspartic acid+α-ketoglutaric acid → AST Oxaloactic acid+L-Glutamic acid. Alanine + α-ketoglutaric acid → ALT Pyruvic acid + L-Glutamic acid. The keto acids produced will form colored hydrazones by reaction with 2, 4-dinitrophenyl hazine.

Determination of total protein

Serum total protein evaluation was performed by the Biuret method, according to Gornall et al.29, using ready-made kits by Stanbio, Texas. The principle is that protein molecules contain a large number of peptides and bonds. When treated with copper ions in alkaline solution, a colored complex is formed between the copper, the carbonyl and amine groups of these peptides. As a similar reaction occurs with biuret, the term “biuret reaction” was adopted.

Determination of albumin

The plasma albumin was determined, using Stanbio albumin kit, purchased from Stanbio Laboratory Inc., Boerne, Texas, USA according to the method of Doumas et al.30.

Determination of globulin

The plasma globulin was calculated by subtracting albumin values from total protein of each corresponding sample. The albumin to globulin ratio (A/G) was calculated by dividing A/G values.

Determination of the brain monoamines and metabolite concentrations by HPLC method

The HPLC system consisted of quaternary pump, a column oven, Rheodine injector, 20-μl loop and UV variable wavelength detector. The report and chromatogram were taken from a data acquisition program, purchased from Chemstation. The sample was immediately extracted from the trace elements and lipids by the use of solid phase extraction Chromabond column NH2 phase, cat. No.730031. The sample was then injected directly into an AQUA column 150 mm 5μ C18, purchased from Phenomenex, USA under the following conditions: mobile phase 20mM potassium phosphate, pH 2.5, flow rate 1.5ml/minute, UV 270 nm31.

Antioxidant parameters

Determination of brain MDA by HPLC

MDA standard was prepared by dissolving 25 μl 1,1,3,3 tetraethoxypropane (TEP) in 100 ml of water to get a 1 mM stock solution. The working standard was prepared by hydrolysis of 1 ml TEP stock solution in 50 ml 1% sulfuric acid and incubated for 2h at room temperature. The resulting MDA standard of 20 nmol/ml was further diluted with 1% sulfuric acid to yield the final concentration of 1.25 nmol/ml, which was used as the standard for the estimation of total MDA32.

Determination of brain GSH and GSSG by HPLC

The thiols compounds of oxidized and reduced glutathione were detected by HPLC using the previously described method33.

Determination of brain nitrites and nitrates by HPLC

Nitrites and nitrates were determined by HPLC according to the method by Papadoyannis et al. 34.

Determination of SOD in liver

The activity of SOD was determined according to the method of Marklund and Marklund 35.

Determination of brain 8-OHDG

Isolation and hydrolysis of brain DNA was performed as previously described by Lodovici et al. 36. The hydrolyzed mixture was centrifuged, and the supernatant was injected into the HPLC. The separation of 8-OHDG was performed by a LC/Agilent 1200 series HPLC apparatus (USA), using UV detectors. For chromatographic separation, we used C18 reverse phase columns in series (Supelco, 5 pm, I.D. 0.46 × 25 cm); the eluting solution was H2O /CH2OH (85: 15 v/v) with 50 mM KH3PO4, pH 5.5 at a flow rate of 0.68 ml/minute. The UV detector was set at 245 nm 37. The resulting chromatogram identified the concentration from the sample as compared to that of the standard, purchased from Sigma Aldrich.

Determination of adenosine tri-phosphate content (ATP, ADP and AMP) in brain tissues by HPLC

Rapid high performance liquid chromatography method was developed for determination of adenine nucleotides in different tissues, which was used to investigate the relation between regional blood flow and tissue contents of compounds, involved in energy metabolism under physiological and pathological conditions. The detection of ATP was performed by HPLC 38.

Statistical analysis

Statistical analysis of the obtained behavioral data was performed using nonparametric statistics Kruskal–Wallis test, followed by Mann–Whitney U test. Other parameters were done using Statistical Analysis Systems Institute (SAS, 1989). Significant differences among means were evaluated using Duncan’s Multiple Range Test. The following linear model was applied:

Yij = μ + αi + ξij

Yij= Observation measured

μ = Overall mean

ξIj = Experimental error assumed to be randomly distributed (σ2 = 0).

Results

Behavioral test

Figure 2 . Effect of Flux and /or HVE on behavioral open field test in reserpine-induced depressed rats model.

Figure 3 . Effect of Flux and /or HVE on behavioral force swimming test in reserpine induced depressed rats model.

Figure 2 shows the effect of an anti-hypertensive drug (Res), which induced rat depression model, confirmed by an open field behavioral test. The test shows a decrease in rearing and duration time in the peripheral zone. In contrast, other parameters of the open field for Res group showed a significant increase in grooming, duration at central zone, urination and defecation. According to Flux, HVE and their combination, obtained results demonstrated that the depression parameters are rested to the normal condition and markedly ameliorated from Res group.

Figure 3 shows the effect of Res in the spider shape of depression induction in rat model, resembling in increasing fluting, immobility time, decreased swimming, and climbing time. On the other hand, Flux group showed strength shape for climbing on another group and amelioration for swimming time with reduction in fluting time. In the same manner, HVE and HVE, plus Flux showed a marginal amelioration of the depression condition, which resulted in increased swimming time and decreased duration of fluting, or immobility time.

Figure 4 . Effect of Flux and/or HVE on brain monoamines concentration in reserpine induced depressed rat model . Data are expressed as Mean ± SEM for six rats/group. a, b, c means having different superscript letters in the same column differ significantly (p < 0.05).

Table 1.

Effect of Flux and /or HVE and their combination on serum liver function in reserpine-induced depressed rats model

Groups Parameters
ALTIU/L ASTIU/L TPg/dL Albg/dL Globg/dL A/G
Control (n=6) 24.85 ± 0.80e 25.75 ± 0.97e 7.69 ± 0.22a 4.29 ± 0.13a 3.4 ± 0.14a 1.26 ± 0.04ab
Res (n=6) 49.84 ± 1.57a 55.5 ± 1.55a 6.94 ± 0.23b 3.99 ± 0.12a 2.95 ± 0.09b 1.35 ± 0.04a
Res+Flux (n=6) 42.89 ± 1.6b 47.95 ± 1.72b 7.03 ± 0.21b 4.11 ± 0.13a 2.92 ± 0.11b 1.4 ± 0.045a
HVE (n=6) 30.03 ± 1.09d 36.58 ± 1.07d 7.72 ± 0.25a 4.16 ± 0.14a 3.62 ± 0.11a 1.16 ± 0.038b
Res+Flux+HVE (n=6) 36.95 ± 1.21c 42.6 ± 1.60c 7.55 ± 0.22a 4.07 ± 0.12a 3.48 ± 0.10a 1.16 ± 0.046b

Liver functions

Obtained data of Table 1 shows initial reduction in liver function and leakage of enzymes from hepatocytes after sub-chronic dose of Res, which resulted in a real increase of ALT, AST and a significant decrease of TP, comparing with the control group. In the same manner, Flux showed a similar trend for hepatocytes degradation. In contrast, HVE did not show harmful effects and ameliorated liver function to almost a normal condition. It also decreased the side effect of Flux in the combination group, compared to control group.

Table 2.

Effect of Flux and HVE and their combination on brain monoamines concentration in reserpine-induced depressed rats model

Groups Parameters
NE μg/g tissue DA μg/g tissue 5HT μg/g tissue
Control (n=6) 0.566 ± 0.021a 2.41 ± 0.094a 0.472 ± 0.017a
Res (n=6) 0.277 ± 0.012d 1.19 ± 0.033d 0.24 ± 0.009d
Res+Flux (n=6) 0.381 ± 0.012bc 1.61 ± 0.029bc 0.288 ± 0.012c
HVE (n=6) 0.353 ± 0.022cd 1.48 ± 0.066c 0.314 ± 0.014bc
Res+Flux+HVE (n=6) 0.435 ± 0.020b 1.74 ± 0.078b 0.359 ± 0.018b

Brain monoamines and their metabolites

The data in Table 2 suggests a significant attrition for monoamines, compared to the control group. In contrast, the groups, treated with Flux, HVE, and their combination showed results, almost similar to the control group and significantly different from the Res group.

Figure 4 shows an excessive disturbance in metabolites of DA, such as DOPAC and HVA, serotonin, 5HIAA, resembling in decrease of DA metabolites and significant increase of 5HIAA for the Res group, comparing with the control group. In addition, the Flux and combined groups with HVE showed the recovery of all metabolites. The results were almost similar to the control group and significant different from Res group. Indeed, HVE showed amelioration of DOPAC, relative to the Res group and mild, but insignificant recovery for HVA and 5HIAA.

Table 3.

Effect of Flux and/or HVE on brain oxidative stress markers in reserpine-induced depressed rats model

Groups Parameters
MDA nmol/g tissue GSHμmol/g tissue GSSG μmol/g tissue NO μmol/g tissue SOD U/g tissue
Control (n=6) 16.92 ± 0.41e 4.003 ± 0.26a 0.514 ± 0.02c 0.39 ± 0.02d 54.25 ± 1.88a
Res (n=6) 55.10 ± 3.04a 1.583 ± 0.09c 1.41 ± 0.054a 1.03 ± 0.08a 22.98 ± 0.89e
Res+Flux (n=6) 33.01 ± 1. 90b 2.105 ± 0.21bc 0.954 ± 0.03ab 0.66 ± 0.05bc 34.62 ± 1.22d
HVE (n=6) 24.95 ± 1.74d 2.963 ± 0.16b 0.745 ± 0.03b 0.58 ± 0.06c 48.62 ± 1.71b
Res+Flux+HVE (n=6) 28.716 ± 1.65c 2.87 ± 0.17b 0.773 ± 0.03b 0.70 ± 0.05b 39.65 ± 1.45c

Brain oxidative stress and neuronal cell energy

Table 3 shows a massive cell membrane degradation, presenting in more than triple level of MDA concentration compared to control group, markedly decreased endogenous antioxidant markers (GSH and SOD) and stimulated nitrositive radical and oxidation due to GSSG production. In the same manner, Flux still described with oxido-nitrositive stimulator and had no effect on antioxidant system. In contrast, the HVE mixed-treated group showed amelioration for cell membrane protective properties, which decreased MDA, GSSG, NO, and increased GSH and SOD, comparing with Res group.

Figure 4 shows a severe brain DNA degradation in Res group and subsequent Res treated with Flux in combination, compared to control group. On the other hand, HVE showed an ameliorating effect and stabilized to normal conditions DNA, with a significant decrease from the Res and Flux, but with significant differences, compared to control group.

Table 4.

Effect of Flux and/or HVE on brain cell energy in reserpine-induced depressed rats model

Groups Parameters
ATP μg/g tissue ADP μg/g tissue AMP μg/g tissue
Control (n=6) 23.73 ± 1.08a 12.68 ± 0.74a 7.01 ± 0.35a
Res (n=6) 11.47 ± 0.26d 5.01 ± 0.14d 3.09 ± 0.23c
Res+Flux (n=6) 14.45 ± 0.51c 7.10 ± 0.42c 4.10 ± 0.18c
HVE (n=6) 18.64 ± 0.96b 10.37 ± 0.41b 5.95 ± 0.26b
Res+Flux+HVE (n=6) 17.88 ± 0.61b 9.14 ± 0.28b 5.16 ± 0.22b

Obtained data in Table 4 shows significant cell energy exhaustion in terms of ATP, ADP, and AMP in Res group compared to control group. In addition, there was a significant amelioration for cell energy in the brain for HVE and HVE combined with Flux treated group which ameliorate energy capacity of neurons.

Figure 5 . Effect of Flux and/or HVE on metabolite of brain DNA (8OHdG) in reserpine induced depressed rats model.

Discussion

Antihypertensive drugs, such as reserpine, are naturally extracted indole alkaloids, acting as a dopamine depletion agent, that inhibits several neurotransmitters39. According to a planned investigated study, Res showed identical effects of reserpine as a depressive model demonstration in behavioral tests, which increased immobility and swimming or climbing time. That is due to monoamines depletion. In addition, depression model was confirmed by OFT by means of increased central duration time, defecation, urination ad grooming behavior; in contrast, locomotor activity, resembling in peripheral zone and rearing time were decreased, comparing with the control group. The present finding showed that a reference drug SSRI stimulated serotonin production, stimulated locomotor activity through increasing clamping, fluting time and OFT excitatory parameters (rearing and duration of stay in peripheral zone). All the recorded results about HVE for behavioral test may bake to normal condition for each behavioral tests, but swimming time is more of a marker for normalized behavioral FST, than clamping, which reflects chemical serotonin stimulation and increased locomotor activity without abnormal excitation. These findings are in agreement with previous study of Preskorn et al. 40 which proved, that the flavonoid (Resveratrol) stabilized behavioral state for Res induced depression, thus it was effective as a natural antidepressant, which may be capable of reversing the depressive-like effects of reserpine. Similarly, a combined treatment for behavioral tests showed the best treatment, which normalized swimming and decreased fluting time. Indeed, exerted beneficial effects for both herbal remedy and SSRI treatment with minor side effects. Present data showed a significant side effect for Res, which displayed toxic effects due to the indole alkaloids. The highest toxicity values of indole alkaloids were owing to tryptamine, which had the least active alkaloid and other chemicals to restrict the reason of phytotoxicity for auxins with an aromatic ring and a side chain which arise from changes of the length of the side chain and changes on the structure of the amino group. Res established a depression rat model via the decrease of all neurotransmitters and damaging liver and brain neurons. According to biochemical parameters, the Res group showed decreased level of endogenous antioxidants, increased redox status and decreased cell energy. All alterations were confirmed by histopathological examination, which reflects the evacuation and picnotic neurons and spreading neuropil in wide distribution. In the same manner, a previous study of Owens et al. 41 showed that Res increases TBA, which resembles an increase in MDA concentration and decrease of GSH levels in brain and liver tissues. This could be due to the pathophysiology of multiple pathogenic factors, involved in depression and concurrent with monoaminergic depletion.

The SSRIs induced blocking the reuptake of serotonin, leading to increased concentration of the neurotransmitters in the synaptic cleft and, ultimately, to greater postsynaptic neuronal activity42. Fluoxetine and its major metabolite, norfluoxetine, are highly active against serotonin transport and also may have antimigraine effects not found with the (R)-enantiomer of fluoxetine43. The (R)-enantiomer of fluoxetine is active against serotonin transport and is short-acting44. An increased synaptic availability of serotonin stimulates a large number of postsynaptic 5-HT receptor types 45. Stimulation of 5-HT3 receptors is hypothesized to contribute to common adverse effects, including gastrointestinal and sexual dysfunction. Demonstrated data clearly concurred with Schatzberg44, who found that the decrease in depression adult rats, treated with Flux might be due to neuroadaptive mechanisms via monoamines stabilization. On the other hand, presented data remarked beneficial effects for Flux-treated group, but in the same way showed the prissiness of side effects, resulting in liver alteration. Due to a lower ability to metabolize serotonin and a lower capacity of glomerular filtration rate, psychotropic drugs quickly produced craniofacial malformations for embryonic rats 46. Another side effect of SSRIs, that has been evaluated in experimental studies, is the decrease in brain cell energy, especially ATP content, which was confirmed by Süzme 47, who reported that fluoxetine and other SSRIs induced negative effects, which postulated bound SSRIs to sulfhydryl groups in the cell membrane and impaired ATP synthesis, by interacting with phospholipids. In the prissiness of data, liver alteration was confirmed by a histopathological examination. This fact is in agreement with Reichelt 48, who reported that the major finding of Flux treated rats was the development of hepatocellular hydropic vacuolar degeneration. Similarly, Sugimoto et al. 49 examined hepatic glycogen content and confirmed that the vacuoles did not contain glycogen. Since hepatic protein contents decreased in parallel with the severity of hepatocellular vacuolar degeneration, the vacuoles were considered to be mainly associated with intracellular water accumulation. Insulin and glucagon were recently recognized as potent modulators of liver cell volume. These findings may be due to serotonin, a cause of hypoglycemia, and an increase in serum insulin levels50. Insulin stimulates Na+-H+ exchange, Na+-K+ -2Cl transport, and Na+-K+ -ATPase, and the concerted action of these transporters lead to cellular accumulation of K+, Na+ and Cl- and, consequently, cell swelling51. The exposure of the brain to Res induced depression and subsequent oxido-nitrisitve stress, which is a one of the most important risk factors for neurodegenerative diseases. Hordeum vulgare extract can mitigate each afore negative effect due to its contents, which is rich in flavonoids, carotenoids, vitamins, and amino acids, especially tyrosine. According to the present study, HVE showed amelioration in liver function and decreased enzyme leakage to the blood stream. In addition, a decreased brain oxido-nitrositive stress and normalized GSH and enzymatic antioxidant marker (SOD) were shown, which may be due to antioxidative properties. The obtained data are consistent with Held 52, who reported that HVE is a powerful antioxidant due to free radical scavenging activity, inhibition of lipoxygenase activity and inhibition of b-carotene co-oxidation in a linoleate model system. In the same manner, Boekema and Braun53 showed a significant decrease in MDA level whereas increase the SOD, GSH content and CAT activities with HVE, as compared to gentamicin-induced nephrotoxicity in adult male rats. According to the main active constituent of HVE for neuro-deficiency function (Tyrosine), it can be identified as a semi-essential aromatic amino acid54. It is responsible for the syntheses of catecholamines (NE and DA), thyroid hormone and melanin pigmentation53. The brain contains a large number of mitochondria and produces much energy through mitochondrial oxidative phosphorylation55. The recovery of monoamines may normalize ATP and its metabolites ADP and AMP, or mild depletion, according to the depression model, may stimulate ATP as a neuromodulator for compensating DA depletion, or monoamines deficiency. In the present study, a combination of HVE extract with Flux effects on brain neurotransmitters showed effectiveness of D2 agonist and stimulate secretion via tyrosine rich extract that precursor of DA and tryptophane of serotonin stimulant56. The focus of obtained data was to establish the mechanism, how barley ameliorates depression via tryptophan content. It has been identified that a large percentage of tryptophan increase in brain tryptamine concentration leads to accelerated synthesis of 5-HT57.

Conclusion

In conclusion, obtained data highlighted the vital and neural role of corrective depression, induced by reserpine with spontaneous treatment by HVE, stimulating monoamines, antioxidant status, decrease oxidonitrositive markers and increase cell energy capacity without side effects on liver. In contrast, SSRI drugs shown to induce liver damage.

Competing Interests

None of the authors of this article have conflicting interests.

Authors’ contributions

All authors contributed equally in the study design, interpretation of the data, and writing of the final manuscript.

References

  1. McKeever A., Agius M., Mohr P., Review of the epidemiology of major depressive disorder and of its consequences for society and the individual. Psychiatria Danubina. 2017; 29 (3) : 222-31 .
    PubMed    Google Scholar 
  2. Ferrari A.J., Somerville A.J., Baxter A.J., Norman R., Patten S.B., Vos T., Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychological Medicine. 2013; 43 (3) : 471-81 .
    View Article    PubMed    Google Scholar 
  3. Hyman S.E., The genetics of mental illness: implications for practice. Bulletin of the World Health Organization. 2000; 78 (4) : 455-63 .
    PubMed    Google Scholar 
  4. Simon G.E., Treating depression in patients with chronic disease: recognition and treatment are crucial; depression worsens the course of a chronic illness. The Western Journal of Medicine. 2001; 175 (5) : 292-3 .
    View Article    PubMed    Google Scholar 
  5. Dunn E.C., Brown R.C., Dai Y., Rosand J., Nugent N.R., Amstadter A.B., Genetic determinants of depression: recent findings and future directions. Harvard Review of Psychiatry. 2015; 23 (1) : 1-18 .
    View Article    PubMed    Google Scholar 
  6. Melle I., Larsen T.K., Haahr U., Friis S., Johannesen J.O., Opjordsmoen S., Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis. Archives of General Psychiatry. 2008; 65 (6) : 634-40 .
    View Article    PubMed    Google Scholar 
  7. Roozen H.G., de Waart R., van der Kroft P., Community reinforcement and family training: an effective option to engage treatment-resistant substance-abusing individuals in treatment. Addiction (Abingdon, England). 2010; 105 (10) : 1729-38 .
    View Article    PubMed    Google Scholar 
  8. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003; 301 (5631) : 386-9 .
    View Article    PubMed    Google Scholar 
  9. Patten S.B., Are the Brown and Harris "vulnerability factors" risk factors for depression?. Journal of Psychiatry & Neuroscience. 1991; 16 (5) : 267-71 .
    PubMed    Google Scholar 
  10. van der Deure W.M., Appelhof B.C., Peeters R.P., Wiersinga W.M., Wekking E.M., Huyser J., Polymorphisms in the brain-specific thyroid hormone transporter OATP1C1 are associated with fatigue and depression in hypothyroid patients. Clinical Endocrinology. 2008; 69 (5) : 804-11 .
    View Article    PubMed    Google Scholar 
  11. Ferguson J.M., Ferguson MD. SSRI antidepressant medications: adverse effects and tolerability. Primary Care Companion to the Journal of Clinical Psychiatry. 2001; 3 (1) : 22-7 .
    View Article    PubMed    Google Scholar 
  12. Marken P.A., Munro J.S., Selecting a selective serotonin reuptake inhibitor: clinically important distinguishing features. Primary Care Companion to the Journal of Clinical Psychiatry. 2000; 2 (6) : 205-10 .
    View Article    PubMed    Google Scholar 
  13. Frasure-Smith N., Lespérance F., Juneau M., Talajic M., Bourassa M.G., Gender, depression, and one-year prognosis after myocardial infarction. Psychosomatic Medicine. 1999; 61 (1) : 26-37 .
    View Article    PubMed    Google Scholar 
  14. Goldstein B.J., Goodnick P.J., Selective serotonin reuptake inhibitors in the treatment of affective disorders, 3: tolerability, safety, and pharmacoeconomics. J Psychopharmacol . 1998; 87 (B) : S55-87 .
  15. Nelson J.C., Safety and tolerability of the new antidepressants. The Journal of Clinical Psychiatry. 1997; 58 (6) : 26-31 .
    PubMed    Google Scholar 
  16. Fr∅lich W., Aman P., Tetens I., Whole grain foods and health - a Scandinavian perspective. Food & Nutrition Research. 2013; 57 (6) : 57-66 .
    View Article    PubMed    Google Scholar 
  17. Baik B.K., Ullrich S.E., Barley for food: characteristics, improvement, and renewed interest. J Cereal Sci . 2008; (48) : 233e42 .
  18. Dongowski G., Huth M., Gebhardt E., Flamme W., Dietary fiber-rich barley products beneficially affect the intestinal tract of rats. The Journal of Nutrition. 2002; 132 (12) : 3704-14 .
    View Article    PubMed    Google Scholar 
  19. Saunders J.A., Saunders J.M., Morris S., Wynne S.A., Amino acid analysis of subcellular fractions by PITC and OPA. Chromatogram. 1988; 9 (1) : 2-4 .
  20. Ahmed N.Z., Ahmed-Farid O.A., Assessment of in-vitro and in-vivo bioactivities potential of some Egyptian wild plants as anti-ulcerogenic effect on male albino rats. Pharmaceutical Chemistry Journal. 2017; 4 (6) : 68-86 .
  21. Siddhuraju P., Becker K., The antioxidant and free radical scavenging activities of processed cowpea (Vigna unguiculata) (L.) seeds extracts. J Food Chem. 2007; 101 (1) : 10-9 .
    View Article    Google Scholar 
  22. Ahmed R.F., Abdel-Rahmana R.F., Abdallaha H.M., Saleha D.O., Ahmed-Farid O.A., Hessina A.F., Antidepressant-like effect of resveratrol in a subchronic model of depression. Soc Med Res. 2014; 9 (2) : 48-53 .
  23. Ahmed-Farid O.A., Ahmed R.F., Saleh D.O., Combination of resveratrol and fluoxetine in an acute model of depression in mice: Prevention of oxidative DNA fragmentation and monoamines degradation. J Appl Pharm Sci. 2016; 6 (6) : 1-7 .
  24. Patel R., Shah J.G., Protective effect of ethanolic extract of Hordeum vulgare seed on gentamicin induced nephrotoxicity. Int Res J Pharm. 2017; 8 (8) : 1-6 .
    View Article    Google Scholar 
  25. Moore D.M., Hematology of rabbitsLippincott Williams and Wilkins: Philadelphia, USA; 2000.
    Google Scholar 
  26. Xu Y., Wang Z., You W., Zhang X., Li S., Barish P.A., Antidepressant-like effect of trans-resveratrol: involvement of serotonin and noradrenaline system. European Neuropsychopharmacology. 2010; 20 (6) : 405-13 .
    View Article    PubMed    Google Scholar 
  27. Porsolt R.D., Le Pichon M., Jalfre M., Depression: a new animal model sensitive to antidepressant treatments. Nature. 1977; 266 (5604) : 730-2 .
    View Article    PubMed    Google Scholar 
  28. Reitman S., Frankel S., A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. American Journal of Clinical Pathology. 1957; 28 (1) : 56-63 .
    View Article    PubMed    Google Scholar 
  29. Gornall A.G., Bardawill C.J., David M.M., Determination of serum proteins by means of the biuret reaction. The Journal of Biological Chemistry. 1949; 177 (2) : 751-66 .
    PubMed    Google Scholar 
  30. Doumas B.T., Watson W.A., Biggs H.G., Albumin standards and the measurement of serum albumin with bromcresol green. Clinica Chimica Acta. 1971; 31 (1) : 87-96 .
    View Article    PubMed    Google Scholar 
  31. Pagel P., Blome J., Wolf H.U., High-performance liquid chromatographic separation and measurement of various biogenic compounds possibly involved in the pathomechanism of Parkinson's disease. Journal of Chromatography. B, Biomedical Sciences and Applications. 2000; 746 (2) : 297-304 .
    View Article    PubMed    Google Scholar 
  32. Karatep M., Simulatenous determination of ascorbic acid and free malondialdehyde in human serum by HPLC-UV. Chromatogr Line. 2004; 12 : 362-5 .
  33. Jayatilleke E., Shaw S., A high-performance liquid chromatographic assay for reduced and oxidized glutathione in biological samples. Analytical Biochemistry. 1993; 214 (2) : 452-7 .
    View Article    PubMed    Google Scholar 
  34. Papadoyannis L.N., Samanidou V.F., Nitsos C.C., Simultaneous determination of nitrite and nitrate in drinking water and human serum by high performance anion-exchange chromatography and UV detection. J Liq Chrom Rel Technol. 1999; 22 (13) : 2023-41 .
    View Article    Google Scholar 
  35. Marklund S., Marklund G., Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. European Journal of Biochemistry. 1974; 47 (3) : 469-74 .
    View Article    PubMed    Google Scholar 
  36. Lodovici M., Casalini C., Briani C., Dolara P., Oxidative liver DNA damage in rats treated with pesticide mixtures. Toxicology. 1997; 117 (1) : 55-60 .
    View Article    PubMed    Google Scholar 
  37. Teerlink T., Hennekes M., Bussemaker J., Groeneveld J., Simultaneous determination of creatine compounds and adenine nucleotides in myocardial tissue by high-performance liquid chromatography. Analytical Biochemistry. 1993; 214 (1) : 278-83 .
    View Article    PubMed    Google Scholar 
  38. Banchroft J.D., Stevens A., Turner D.R., Churchill Livingstone: New York, London, San Francisco, Tokyo; 1996.
    Google Scholar 
  39. Yaffe D., Forrest L.R., Schuldiner S., The ins and outs of vesicular monoamine transporters. The Journal of General Physiology. 2018; 150 (5) : 671-82 .
    View Article    PubMed    Google Scholar 
  40. Preskorn S.H., Ross R., Stanga C.Y., . Antidepressants: Past, Present and FutureSpringer: Berlin, Germany; 2004.
    View Article    Google Scholar 
  41. Owens J.M., Knight D.L., Nemeroff C.B., Second generation SSRIS: Human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2002; 28 (4) : 350-5 .
    View Article    Google Scholar 
  42. Fuller R.W., Snoddy H.D., Krushinski J.H., Robertson D.W., Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropharmacology. 1992; 31 (10) : 997-1000 .
    View Article    PubMed    Google Scholar 
  43. Azmitia E.C., Rubinstein V.J., Strafaci J.A., Rios J.C., Whitaker-Azmitia P.M., 5-HT1A agonist and dexamethasone reversal of para-chloroamphetamine induced loss of MAP-2 and synaptophysin immunoreactivity in adult rat brain. Brain Research. 1995; 677 (2) : 181-92 .
    View Article    PubMed    Google Scholar 
  44. Schatzberg A., Cole J., American Psychiatric Press: Washington (DC); 1991.
    Google Scholar 
  45. Shuey D.L., Sadler T.W., Lauder J.M., Serotonin as a regulator of craniofacial morphogenesis: site specific malformations following exposure to serotonin uptake inhibitors. Teratology. 1992; 46 (4) : 367-78 .
    View Article    PubMed    Google Scholar 
  46. Reid T.E., Kumar K., Wang X.S., Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart disease. Current Topics in Medicinal Chemistry. 2013; 13 (11) : 1353-62 .
    View Article    PubMed    Google Scholar 
  47. Süzme R., Gürdöl F., Deniz G., Ozden T., Response in DNA ploidy of hepatocytes to tamoxifen and/or melatonin in vivo. Research Communications in Molecular Pathology and Pharmacology. 2001; 109 (5-6) : 275-86 .
    PubMed    Google Scholar 
  48. Reichelt M.E., Mellor K.M., Curl C.L., Stapleton D., Delbridge L.M., Myocardial glycophagy - a specific glycogen handling response to metabolic stress is accentuated in the female heart. Journal of Molecular and Cellular Cardiology. 2013; 65 : 67-75 .
    View Article    PubMed    Google Scholar 
  49. Sugimoto Y., Kimura I., Yamada J., Watanabe Y., Takeuchi N., Horisaka K., Effects of serotonin on blood glucose and insulin levels of glucose- and streptozotocin-treated mice. Japanese Journal of Pharmacology. 1990; 54 (1) : 93-6 .
    View Article    PubMed    Google Scholar 
  50. Hallbrucker C., vom Dahl S., Lang F., Gerok W., Häussinger D., Inhibition of hepatic proteolysis by insulin. Role of hormone-induced alterations of the cellular K+ balance. European Journal of Biochemistry. 1991; 199 (2) : 467-74 .
    View Article    PubMed    Google Scholar 
  51. Goupy P., Hugues M., Boivin P., Amiot M.J., Antioxidant composition and activity of barley (Hordeum vulgare) and malt extracts and of isolated phenolic compounds. Journal of the Science of Food and Agriculture. 1999; 79 (12) : 1625-34 .
    View Article    Google Scholar 
  52. Held P.K., Disorders of tyrosine catabolism. Molecular Genetics and Metabolism. 2006; 88 (2) : 103-6 .
    View Article    PubMed    Google Scholar 
  53. Boekema E.J., Braun H.P., Supramolecular structure of the mitochondrial oxidative phosphorylation system. The Journal of Biological Chemistry. 2007; 282 (1) : 1-4 .
    View Article    PubMed    Google Scholar 
  54. Khan A., Schwartz K.A., Kolts R.L., Brown W.A., BMI, sex, and antidepressant response. Journal of Affective Disorders. 2007; 99 (1-3) : 101-6 .
    View Article    PubMed    Google Scholar 
  55. Mullur R., Liu Y.Y., Brent G.A., Thyroid hormone regulation of metabolism. Physiological Reviews. 2014; 94 (2) : 355-82 .
    View Article    PubMed    Google Scholar 
  56. Robinson O.J., Standing H.R., DeVito E.E., Cools R., Sahakian B.J., Dopamine precursor depletion improves punishment prediction during reversal learning in healthy females but not males. Psychopharmacology. 2010; 211 (2) : 187-95 .
    View Article    PubMed    Google Scholar 
  57. Warsh J.J., Godse D.D., Stancer H.C., Chan P.W., Coscina D.V., Brain tryptamine in rats by a new gas chromatography-mas fragmentographic method. Biochemical Medicine. 1977; 18 (1) : 10-20 .
    View Article    PubMed    Google Scholar 

Comments